Xiaodan He, Jingshi Wang, Zhao Wang^*

Oncologie, Vol.23, No.4, pp. 559-567, 2021, DOI:10.32604/oncologie.2021.018647 - 31 December 2021

Abstract Despite extensive work-ups, some patients have been diagnosed with hemophagocytic lymphohistiocytosis (HLH) of unknown etiology. For HLH of unknown etiology, to investigate the clinical features and the factors that may affect the prognosis, we retrospectively reviewed the medical records of 94 patients hospitalized from January 2014 to December 2019. Survival times were evaluated until April 2020. For the 94 patients, the underlying causes of their diseases remained unclear at the end of the follow-up period, and the 1-, 3-, and 6-month survival rates, and the overall survival (OS) rates were 86.2%, 78.7%, 73.4%, and 70.2%,… More >

MAYSON H. ALKHATIB^1,2,*, SALWA M. AL-HASHEMI¹, HANA M. GASHLAN¹

BIOCELL, Vol.45, No.3, pp. 695-703, 2021, DOI:10.32604/biocell.2021.014349 - 03 March 2021

Abstract Incorporation of etoposide (ETP) into nanoemulsion (NE) containing polyunsaturated fatty acids (PUFAs) may potentially augment its antiproliferation effect on the cancer cells. The current study aimed to examine the in vitro antitumor activity of a novel formulation (ETP-BC/EP-NE) produced by combining the anticancer drug (ETP) with NE (BC/EP-NE) consisting of the black currant seed and organic evening primrose oils. The produced formulas were physically characterized using zetasizer measurements. Their cytotoxic effect was testified at concentrations ranges from 0.0001 to 5 μM using CCK-8. Apoptotic and anti-invasion effects were evaluated using the assays of mitochondrial membrane potential,… More >

Wei Ni^*†‡, Lin Luo^*†‡, Ping Zuo^*†‡, Renping Li^*†‡, Xiaobing Xu^*†‡, Fan Wen^*†‡, Dong Hu^*†‡

Oncology Research, Vol.27, No.6, pp. 703-712, 2019, DOI:10.3727/096504018X15426775024905

Abstract Glioma is a commonly diagnosed brain tumor that shows high mortality rate. Despite the great advancement of cancer therapy in recent years, chemotherapy is still an important approach for treatment of glioma. However, long-term chemotherapy usually causes serious side effects or complications. It is desirable to take strategies to enhance the efficacy of current chemotherapy. In the present study, we observed obvious upregulation of miR-374a in glioma cells. More importantly, we found that knockdown of miR-374a was able to enhance the etoposide-induced cytotoxicity against glioma cells. Mechanically, we demonstrated that FOXO1 was the target of More >

Annie Im, Ali Amjad, Mounzer Agha, Anastasios Raptis, Jing-Zhou Hou, Rafic Farah, Seah Lim, Alison Sehgal, Kathleen A. Dorritie, Robert L. Redner, Brian McLaughlin, Yongli Shuai, Shrina Duggal, Michael Boyiadzis

Oncology Research, Vol.24, No.2, pp. 73-80, 2016, DOI:10.3727/096504016X14586627440156

Abstract Relapsed acute myeloid leukemia (AML) represents a major therapeutic challenge. Achieving complete remission (CR) with salvage chemotherapy is the first goal of therapy for relapsed AML. However, there is no standard salvage chemotherapy. The current study evaluated outcomes and prognostic factors for achievement of CR in 91 AML patients in first relapse who were treated with the mitoxantrone–etoposide combination regimen. The overall response rate (CR and CRi) was 25%. Factors that were associated with a lower rate of CR included older age, shorter duration of first CR, low hemoglobin, and low platelet count. The median… More >